解开介素-1β抑制:对抗炎性疾病的抗炎性化合物选择的计算洞察
Madiha Sardar1, Ali Raza Siddiqui1, Nadeem Ahmad1
1H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.
Journal of molecular graphics & modelling
|December 9, 2024
概括
针对介素-1β (IL-1β) 和其受体 (IL-1R1) 的新型小分子显示出治疗炎症疾病的前景. 这些化合物有效抑制蛋白质-蛋白质相互作用,为失败的疗法提供了潜在的替代方案.
科学领域:
- 免疫学和药理学
- 计算化学和药物发现
背景情况:
- 互白素-1β (IL-1β) 在各种免疫反应中起着关键作用,包括炎症和自身免疫性疾病.
- 目前针对IL-1β/IL-1R1相互作用的抑制剂在临床试验中表现出有限的成功.
- 开发新的治疗策略来调节IL-1β信号传递对于管理炎症状况至关重要.
研究的目的:
- 为了确定抑制IL-1β及其受体IL-1R1.1.之间的蛋白质-蛋白质相互作用 (PPI) 的小分子.
- 探索用于治疗IL-1β介导炎症疾病的新型化学型.
主要方法:
- 集成的基于联体的药映射和多阶段的分子对接以选化合物.
- 使用分子动力学 (MD) 模拟和分子力学Poisson-Boltzmann表面积 (MM/PBSA) 计算来评估稳定性和结合亲和力.
- 利用主要组件分析 (PCA) 和自由能源景观 (FEL) 来分析结构动态.
主要成果:
- 选了4万个化合物,确定了8个潜在的匹配物,用于进一步分析.
- 已识别出"内部-2603"和"内部-1325"化合物,具有高稳定性和显著的结合能 (分别为-89.50 ± 10.63 和 -81.32 ± 14.9 kcal/mol).
- MD模拟和MM/PBSA计算证实了已识别的命中物有可能阻碍IL-1β/IL-1R1复合体形成.
结论:
- 鉴定到的小分子表现出稳定的行为和对IL-1β/IL-1R1相互作用的强烈抑制潜力.
- 这些新型PPI抑制剂代表了未来针对炎症性疾病的药物发现工作的有希望的化学型.
- 这项研究为由IL-1β信号驱动的疾病提供了可行的替代治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
Inflammatory Response
1.8K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.8K
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
T Cell Types and Functions
951
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
951
Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349


